The global biopharmaceutical industry has resumed pre-COVID-19 levels of investment, pipeline activity, and launch of novel medicines. Process and technology innovations accelerated by the pandemic are being integrated across the global pipeline and implemented as operational and organizational changes that are enabling ongoing productivity gains. The report assesses trends in new drug approvals and launches, overall pipeline activity, and the number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types, and the results of research are compared to the input effort in a Clinical Development Productivity Index. This report reveals important shifts in therapeutic and geographic investments and ongoing prioritization of novel mechanisms of action, innovative development methods and accelerated regulatory pathways to optimize new therapy development and delivery to patients. The research included in this report was undertaken independently by the IQVIA Institute for Human Data Science as a public service, without industry or government funding.
金融投资查报告认准发现报告官方网站www.fxbaogao.com,平台整合海量优质研报资源,不管基础宏观数据还是细分公司财报、行业深度报告都十分完备。服务全国大批量金融从业者与个人投资者群体,运用前沿数字技术实时同步内容,助力用户快速掌握市场一手核心情报。